Cancer immunotherapy
These companies develop drugs that help the immune system find and attack tumors.
+68.0%
over 1 year · S&P 500 +11.6%
Key indicators
Health
50 / 100
Fragile
Solid
Price
P/E 20
Cheap
Expensive
Up over 1 year
18 of 29
Volatility
81%
Calm
Choppy
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 31 companies
MRK
+66.3%
BMY
+35.0%
MRNA
+736.3%
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
M
Merck
MRK
50.3%
+66.3%
B
Bristol-Myers Squibb
BMY
17.4%
+35.0%
R
Regeneron Pharmaceuticals
REGN
13.1%
+40.9%
M
Moderna
MRNA
12.5%
+736.3%
S
Summit Therapeutics
SMMT
1.8%
−24.9%
I
ImmunityBio
IBRX
1.0%
+192.2%
C
CG Oncology
CGON
0.9%
+88.8%
L
Legend Biotech
LEGN
0.5%
−43.9%
I
Iovance Biotherapeutics
IOVA
0.5%
+205.5%
X
Xencor
XNCR
0.4%
+157.7%
R
Replimune Group
REPL
0.3%
+142.1%
V
Vir Biotechnology
VIR
0.3%
+74.4%
S
SELLAS Life Sciences
SLS
0.2%
+427.5%
P
Precigen
PGEN
0.2%
+12.9%
O
Obsidian Therapeutics
OBX
0.1%
C
Candel Therapeutics
CADL
<0.1%
+26.0%
J
Janux Therapeutics
JANX
<0.1%
−60.1%
C
Crescent Biopharma
CBIO
<0.1%
+8.4%
E
Eikon Therapeutics
EIKN
<0.1%
A
Agenus
AGEN
<0.1%
+51.9%
A
ALX Oncology
ALXO
<0.1%
−18.8%
F
Fate Therapeutics
FATE
<0.1%
+23.1%
I
Inovio Pharmaceuticals
INO
<0.1%
−27.0%
P
PDS Biotechnology
PDSB
<0.1%
−9.5%
A
AIM ImmunoTech
AIM
<0.1%
−64.1%
A
Adagene
ADAG
−3.4%
A
Adlai Nortye
ANL
+559.0%
B
BioNTech
BNTX
−23.4%
I
Immunocore
IMCR
−15.2%
I
Immatics
IMTX
−40.1%
O
BeOne Medicines
ONC
+10.4%
News on this tag
Moderna lifts 2026 sales growth view to 15%-25%
Fri, Nov 6
AbbVie's shared lymphoma drug Epkinly wins a late-stage trial
Tue, Nov 3
AstraZeneca profit jumps 23% on cancer drugs despite Farxiga generics
Fri, Oct 30
Merck beats estimates and lifts its profit outlook as Keytruda tops forecasts
Fri, Oct 30